Ask AI
CDK Inhibitors in Breast Cancer

CE

CDK4/6 Inhibitors in Breast Cancer: An Oncology Nurse’s Toolkit to Enhance Tolerability and Preserve Benefit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: August 15, 2025

Expiration: August 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in your ability to implement recommended strategies to improve adherence to oral CDK4/6 inhibitor therapy in your patients with HR+/HER2- breast cancer?

2.

When counseling a patient with estrogen receptor–positive/HER2-negative breast cancer before starting ribociclib, which initial strategy would you recommend to mitigate diarrhea and improve adherence to therapy?

3.

Patient Case: ER+/HER2- T2N1 BC



  • A 69-yr-old patient with diabetes, congestive heart failure, and arthritis has ER+/HER2- grade 3 BC with 3 positive nodes (T2N1) 

  • She is receiving letrozole and adjuvant zoledronic acid and was recommended adjuvant treatment with CDK4/6i therapy by her oncologist

  • Within 1 mo of starting abemaciclib + AI, she develops grade 2 pneumonitis

How would you manage this patient’s pneumonitis?